RTP Mobile Logo
Questions from the Community: Clinical Investigators Provide Their Perspectives on Challenging Issues and Ongoing Research in the Management of HL and NHL
Released April 2016

Proceedings from Part 1 of a 2-part satellite symposia series during the 57th ASH Annual Meeting. Featuring perspectives from Drs Martin Dreyling, Christopher Flowers, Owen A O’Connor, Sonali M Smith, Michael E Williams and Anas Younes. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY
    Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases were identified in the United States in the year 2015, and 56,630 individuals died from these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, comprising more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses quite a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a CME symposium during the 57th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of Hodgkin and non-Hodgkin lymphoma (NHL). By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Appraise recent data on therapeutic advances and changing practice standards in the management of Hodgkin lymphoma (HL) and NHL, including chronic lymphocytic leukemia (CLL), and integrate this information, as appropriate, into current clinical care.
    • Appreciate the recent FDA approvals of novel targeted agents — ibrutinib, idelalisib and obinutuzumab — for the treatment of newly diagnosed and relapsed/refractory CLL, and discern how these therapies can be appropriately integrated into routine clinical practice.
    • Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the recent addition of bortezomib, lenalidomide and ibrutinib as FDA-endorsed options.
    • Consider available clinical research reports in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory follicular and diffuse large B-cell lymphoma.
    • Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects from these therapies.
    • Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
    • Incorporate new therapeutic strategies into the best-practice management of HL.
    • Develop an understanding of the biologic rationale for and early efficacy and toxicity data with the use of immunotherapeutic approaches for patients with various lymphoma subtypes.
    • Assess the ongoing clinical trials evaluating innovative investigational approaches for NHL and HL, and obtain consent from appropriate patients for study participation.
    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Martin Dreyling, MD, PhD
    Professor of Medicine
    Department of Medicine III
    University Hospital – LMU Munich
    Munich, Germany

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc; Speaker Honorarium: Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc; Support of IITS: Celgene Corporation, Janssen Biotech Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc.

    Christopher Flowers, MD, MS
    Associate Professor of Hematology and Medical Oncology
    Emory School of Medicine
    Winship Cancer Institute
    Atlanta, Georgia

    Consulting Agreements: Celgene Corporation, OptumRx Inc, Seattle Genetics, Spectrum Pharmaceuticals Inc; Contracted Research: Acerta Pharma, Celgene Corporation, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology; Unpaid Consulting Agreements: Genentech BioOncology, Takeda Oncology.

    Owen A O’Connor, MD, PhD
    Professor of Medicine and Developmental Therapeutics
    Director, Center for Lymphoid Malignancies
    Columbia University Medical Center
    College of Physicians and Surgeons
    NewYork-Presbyterian Hospital
    New York, New York

    Advisory Committee: Mundipharma International Limited, Takeda Oncology; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Mundipharma International Limited, Spectrum Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.

    Sonali M Smith, MD
    Associate Professor
    Section of Hematology/Oncology
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, ImmunogeniX Research LLC, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Data and Safety Monitoring Board: Genentech BioOncology.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology.

    Anas Younes, MD
    Chief, Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Sanofi; Contracted Research: Novartis Pharmaceuticals Corporation; Honorarium: Incyte Corporation, Janssen Biotech Inc, Seattle Genetics, Takeda Oncology; Research Support: Curis Inc, Johnson & Johnson Pharmaceuticals.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Margaret A Deutsch, MD
    Clinical Associate
    Duke Raleigh Hematology-Oncology
    Raleigh, North Carolina

    No relevant conflicts of interest to disclose.

    Lyle Feinstein, MD
    Miami Cancer Institute
    Miami, Florida

    No relevant conflicts of interest to disclose.

    Raymond Lobins, DO
    Hematology/Oncology
    Lake County University Hospitals
    Mentor, Ohio

    No relevant conflicts of interest to disclose.

    Jason Melear, MD
    Texas Oncology
    Austin, Texas

    No relevant conflicts of interest to disclose.

    Neil I Morganstein, MD
    Chair of Leukemia/Lymphoma Board
    Carol G Simon Cancer Center
    Overlook Medical Center
    Summit, New Jersey

    No relevant conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Takeda Oncology and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

Acknowledge and close

View video: